52190-18-8

Basic information

• Product Name: N-Phenyl-1H-indole-3-acetamide
• Synonyms: 2-(1H-Indol-3-yl)acetanilide;N-Phenyl-1H-indole-3-acetamide
• CAS NO: 52190-18-8
• Molecular Formula: C₁₆H₁₄N₂O
• Molecular Weight: 250.2952
• Mol File: 52190-18-8.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 547.5°Cat760mmHg
• Flash Point: 284.9°C
• Appearance: /
• Density: 1.279g/cm³
• Vapor Pressure: 4.86E-12mmHg at 25°C
• Refractive Index: 1.72
• PKA: 14.98±0.70(Predicted)
• CAS DataBase Reference: N-Phenyl-1H-indole-3-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Phenyl-1H-indole-3-acetamide(52190-18-8)
• EPA Substance Registry System: N-Phenyl-1H-indole-3-acetamide(52190-18-8)

Safety Data

• Hazardous Substances Data: 52190-18-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H14N2O/c19-16(18-13-6-2-1-3-7-13)10-12-11-17-15-9-5-4-8-14(12)15/h1-9,11,17H,10H2,(H,18,19)

Upstream product

• 50720-05-3 indolyl acetyl chloride 
• 62-53-3 aniline 
• 87-51-4 indole-3-acetic acid 
• 771-51-7 indole-3-acetonitrile 
• 615-36-1 2-bromoaniline 
• 615-43-0 2-iodophenylamine 
• 914929-95-6 N-(2-bromophenyl)-2-(1H-indol-3-yl)acetamide 
• 70834-02-5 1-imidazol-1-yl-2-(1H-indol-3-yl)-ethanone 

Downstream Products

• 73031-16-0 2-(1H-indol-3-yl)-2-oxo-N-phenylacetamide 
• 857208-58-3 4-oxo-1,4-dihydroquinoline-3-carboxylic acid phenylamide 
• 19611-80-4 [2-(1H-indol-3-yl)ethyl]phenylamine 

Relevant articles and documents

Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root

From an aqueous decoction of the traditional Chinese medicine “ban lan gen” (the Isatis indigotica root), an antiviral natural product CI - 39 was isolated as an NNRTI (non-nucleoside reverse transcriptase inhibitor) (EC50 = 3.40 μM). Its novel structure was determined as methyl (1-methoxy-1H-indol-3-yl)acetamidobenzoate by spectroscopic data and confirmed by single crystal X-ray diffraction. Through synthesis and structure-activity relationship (SAR) investigation of CI - 39 and 57 new derivatives (24 with EC50 values of 0.06–8.55 μM), two optimized derivatives 10f and 10i (EC50: 0.06 μM and 0.06 μM) having activity comparable to that of NVP (EC50 = 0.03 μM) were obtained. Further evaluation verified that 10f and 10i were RT DNA polymerase inhibitors and exhibited better activities and drug resistance folds compared to NVP against seven NNRTI-resistant strains carrying different mutations. Especially, 10i (EC50 = 0.43 μM) was more active to the L100I/K103N double-mutant strain as compared to both NVP (EC50 = 0.76 μM) and EFV (EC50 = 1.08 μM). The molecular docking demonstrated a possible binding pattern between 10i and RT and revealed activity mechanism of 10i against the NNRTI-resistant strains.

Use of indole compounds in radix isatidis, and derivatives thereof in preparation of anti-influenza virus medicines

The invention discloses an application of indole compounds extracted from radix isatidis and represented by general formula (I), and derivatives and pharmaceutically acceptable salts thereof in the preparation of anti-influenza virus medicines or healthcare products, and discloses a preparation method of the compounds, and an application of medicinal compositions containing the compounds in the preparation of the anti-influenza virus medicines or healthcare products.

Indolylcarboxylic acid compound and application thereof in preparation of antitumor drugs

The invention relates to the field of pharmaceutical chemistry and discloses an indolylcarboxylic acid compound represented by a formula (I) shown in the description and an application thereof in the preparation of antitumor drugs. The indolylcarboxylic a